XML 29 R15.htm IDEA: XBRL DOCUMENT
v3.24.2.u1

Investments | 6 Months Ended
--- | ---
Jun. 30, 2024
Schedule of Investments [Abstract] |
Investments | Investments Control and Affiliate Investments As required by the 1940 Act, the Company classifies its investments by level of control. “Control investments” are defined in the 1940 Act as investments in those companies that the Company is deemed to “control”. Under the 1940 Act, the Company is generally deemed to “control” a company in which it has invested if it owns 25% or more of the voting securities of such company or has greater than 50% representation on its board. “Affiliate investments” are investments in those companies that are “affiliated companies” of the Company, as defined in the 1940 Act, which are not control investments. The Company is deemed to be an “affiliate” of a company in which it has invested if it owns 5% or more, but generally less than 25%, of the voting securities of such company. “Non-control/non-affiliate investments” are investments that are neither control investments nor affiliate investments. For purposes of determining the classification of its investments, the Company has included consideration of any voting securities or board appointment rights held by the Adviser Funds. The following table summarizes the Company’s realized gains and losses and changes in unrealized appreciation and depreciation on control and affiliate investments for the three and six months ended June 30, 2024 and 2023.
(in thousands) |  | Three Months Ended June 30, 2024 |  | Six Months Ended June 30, 2024
Portfolio Company(1) |  | Type |  | Fair Value as of June 30, 2024 |  | Interest & Dividend Income |  | Fee Income |  | Net Change in Unrealized Appreciation (Depreciation) |  | Realized Gain (Loss) |  | Interest & Dividend Income |  | Fee Income |  | Net Change in Unrealized Appreciation (Depreciation) |  | Realized Gain (Loss)
Control Investments |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Coronado Aesthetics, LLC |  | Control |  | $ | 186 |  |  | $ | — |  |  | $ | — |  |  | $ | (97) |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | (76) |  |  | $ | — |
Gibraltar Acquisition LLC(2) |  | Control |  | 56,811 |  |  | 1,534 |  |  | 36 |  |  | (1,670) |  |  | — |  |  | 2,567 |  |  | 72 |  |  | (6,291) |  |  | — |
Hercules Adviser LLC(3) |  | Control |  | 42,728 |  |  | 1,751 |  |  | — |  |  | 844 |  |  | — |  |  | 3,503 |  |  | — |  |  | 2,015 |  |  | — |
Tectura Corporation |  | Control |  | 11,534 |  |  | 172 |  |  | — |  |  | (583) |  |  | — |  |  | 344 |  |  | — |  |  | 17 |  |  | — |
Total Control Investments |  | $ | 111,259 |  |  | $ | 3,457 |  |  | $ | 36 |  |  | $ | (1,506) |  |  | $ | — |  |  | $ | 6,414 |  |  | $ | 72 |  |  | $ | (4,335) |  |  | $ | — |
(in thousands) |  | Three Months Ended June 30, 2023 |  | Six Months Ended June 30, 2023
Portfolio Company(1) |  | Type |  | Fair Value as of June 30, 2023 |  | Interest Income |  | Fee Income |  | Net Change in Unrealized Appreciation (Depreciation) |  | Realized Gain (Loss) |  | Interest Income |  | Fee Income |  | Net Change in Unrealized Appreciation (Depreciation) |  | Realized Gain (Loss)
Control Investments |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Coronado Aesthetics, LLC |  | Control |  | $ | 297 |  |  | $ | — |  |  | $ | — |  |  | $ | 41 |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | (22) |  |  | $ | — |
Gibraltar Acquisition, LLC(2) |  | Control |  | 44,392 |  |  | 731 |  |  | 19 |  |  | 2,667 |  |  | — |  |  | 1,527 |  |  | 38 |  |  | 6,402 |  |  | — |
Hercules Adviser LLC |  | Control |  | 39,161 |  |  | 152 |  |  | — |  |  | 2,566 |  |  | — |  |  | 302 |  |  | — |  |  | 8,008 |  |  | — |
Tectura Corporation |  | Control |  | 7,073 |  |  | 172 |  |  | — |  |  | (701) |  |  | — |  |  | 342 |  |  | — |  |  | (969) |  |  | — |
Total Control Investments |  | $ | 90,923 |  |  | $ | 1,055 |  |  | $ | 19 |  |  | $ | 4,573 |  |  | $ | — |  |  | $ | 2,171 |  |  | $ | 38 |  |  | $ | 13,419 |  |  | $ | — |
(1)In accordance with Rules 3-09, 4-08(g), and Rule 10-01(b)(1) of Regulation S-X, (“Rule 3-09”, “Rule 4-08(g)”, and “Rule 10-01(b)(1)”, respectively), the Company must determine if its unconsolidated subsidiaries are considered “significant subsidiaries”. As of June 30, 2024 and June 30, 2023, there were no unconsolidated subsidiaries that are considered “significant subsidiaries”. (2)Gibraltar Acquisition LLC is a wholly-owned subsidiary, which is the holding company for their wholly-owned affiliated portfolio companies, Gibraltar Business Capital, LLC and Gibraltar Equipment Finance, LLC. The subsidiary has no significant assets or liabilities, other than their equity and debt investments and equity interest in Gibraltar Business Capital, LLC and Gibraltar Equipment Finance, LLC, respectively. (3)Hercules Adviser LLC is owned by Hercules Capital Management LLC and presented with Hercules Partner Holdings, LLC which are both wholly owned by the Company. Please refer to “Note 1” for additional disclosure. Portfolio Composition The following table shows the fair value of the Company’s portfolio of investments by asset class as of June 30, 2024 and December 31, 2023:
(in thousands) | June 30, 2024 |  | December 31, 2023
| Investments at Fair Value |  | Percentage of Total Portfolio |  | Investments at Fair Value |  | Percentage of Total Portfolio
Senior Secured Debt | $ | 3,320,419 |  |  | 93.0 | % |  | $ | 2,987,577 |  |  | 92.0 | %
Unsecured Debt | 72,090 |  |  | 2.1 | % |  | 69,722 |  |  | 2.2 | %
Preferred Stock | 46,525 |  |  | 1.3 | % |  | 53,038 |  |  | 1.6 | %
Common Stock | 93,726 |  |  | 2.6 | % |  | 99,132 |  |  | 3.1 | %
Warrants | 28,922 |  |  | 0.8 | % |  | 33,969 |  |  | 1.0 | %
Investment Funds & Vehicles | 6,857 |  |  | 0.2 | % |  | 4,608 |  |  | 0.1 | %
Total | $ | 3,568,539 |  |  | 100.0 | % |  | $ | 3,248,046 |  |  | 100.0 | %
A summary of the Company’s investment portfolio, at value, by geographic location as of June 30, 2024 and December 31, 2023 is shown as follows:
(in thousands) | June 30, 2024 |  | December 31, 2023
| Investments at Fair Value |  | Percentage of Total Portfolio |  | Investments at Fair Value |  | Percentage of Total Portfolio
United States | $ | 3,205,062 |  |  | 89.8 | % |  | $ | 2,861,615 |  |  | 88.1 | %
United Kingdom | 164,218 |  |  | 4.6 | % |  | 222,136 |  |  | 6.9 | %
Netherlands | 92,769 |  |  | 2.6 | % |  | 89,995 |  |  | 2.8 | %
Israel | 78,516 |  |  | 2.2 | % |  | 52,868 |  |  | 1.6 | %
Canada | 16,093 |  |  | 0.5 | % |  | 15,730 |  |  | 0.5 | %
Ireland | 4,476 |  |  | 0.1 | % |  | — |  |  | 0.0 | %
Denmark | 4,183 |  |  | 0.1 | % |  | 4,173 |  |  | 0.1 | %
Singapore | 1,791 |  |  | 0.1 | % |  | — |  |  | 0.0 | %
Germany | 1,030 |  |  | 0.0 | % |  | 1,144 |  |  | 0.0 | %
Other | 401 |  |  | 0.0 | % |  | 385 |  |  | 0.0 | %
Total | $ | 3,568,539 |  |  | 100.0 | % |  | $ | 3,248,046 |  |  | 100.0 | %
The following table shows the fair value of the Company’s portfolio by industry sector as of June 30, 2024 and December 31, 2023:
(in thousands) | June 30, 2024 |  | December 31, 2023
| Investments at Fair Value |  | Percentage of Total Portfolio |  | Investments at Fair Value |  | Percentage of Total Portfolio
Drug Discovery & Development | $ | 1,244,782 |  |  | 34.9 | % |  | $ | 1,257,699 |  |  | 38.7 | %
Software | 948,141 |  |  | 26.6 | % |  | 764,985 |  |  | 23.6 | %
Healthcare Services, Other | 568,751 |  |  | 15.9 | % |  | 300,079 |  |  | 9.3 | %
Consumer & Business Services | 351,632 |  |  | 9.9 | % |  | 525,973 |  |  | 16.2 | %
Diversified Financial Services | 111,312 |  |  | 3.1 | % |  | 114,722 |  |  | 3.5 | %
Information Services | 77,434 |  |  | 2.2 | % |  | 126,605 |  |  | 3.9 | %
Electronics & Computer Hardware | 76,191 |  |  | 2.1 | % |  | 20,324 |  |  | 0.6 | %
Medical Devices & Equipment | 55,653 |  |  | 1.6 | % |  | 22,096 |  |  | 0.7 | %
Space Technologies | 45,498 |  |  | 1.3 | % |  | — |  |  | 0.0 | %
Biotechnology Tools | 35,149 |  |  | 1.0 | % |  | 48,381 |  |  | 1.5 | %
Communications & Networking | 29,778 |  |  | 0.8 | % |  | 29,400 |  |  | 0.9 | %
Sustainable and Renewable Technology | 20,301 |  |  | 0.6 | % |  | 9,581 |  |  | 0.3 | %
Manufacturing Technology | 1,680 |  |  | 0.0 | % |  | 11,006 |  |  | 0.3 | %
Consumer & Business Products | 1,223 |  |  | 0.0 | % |  | 2,589 |  |  | 0.1 | %
Semiconductors | 903 |  |  | 0.0 | % |  | 1,205 |  |  | 0.0 | %
Media/Content/Info | 94 |  |  | 0.0 | % |  | 12,704 |  |  | 0.4 | %
Drug Delivery | 17 |  |  | 0.0 | % |  | 21 |  |  | 0.0 | %
Surgical Devices | — |  |  | 0.0 | % |  | 676 |  |  | 0.0 | %
Total | $ | 3,568,539 |  |  | 100.0 | % |  | $ | 3,248,046 |  |  | 100.0 | %
No single portfolio investment represents more than 10% of the fair value of the Company’s total investments as of June 30, 2024 or December 31, 2023. Concentrations of Credit Risk As of June 30, 2024, the Company’s customers are primarily privately held companies and public companies which are active in the “Drug Discovery & Development”, “Software”, “Healthcare Services, Other”, “Consumer & Business Services”, and “Diversified Financial Services” sectors. These sectors are characterized by high margins, high growth rates, consolidation and product and market extension opportunities. Value for companies in these sectors is often vested in intangible assets and intellectual property. Industry and sector concentrations vary as new loans are recorded and loans are paid off. Investment income, consisting of interest, fees, and recognition of gains on equity and warrant or other equity interests, can fluctuate materially when a loan is paid off or a related warrant or equity interest is sold. Investment income recognized in any given year can be highly concentrated among several portfolio companies. As of June 30, 2024 and December 31, 2023, the Company’s ten largest portfolio companies represented approximately 30.0% and 29.7% of the total fair value of the Company’s investments in portfolio companies, respectively. As of June 30, 2024 and December 31, 2023, the Company had five and five portfolio companies, respectively, that represented 5% or more of the Company’s net assets. As of June 30, 2024 and December 31, 2023, the Company had four and five equity investments, respectively, that represented 5% or more of the total fair value of the Company’s equity investments. These equity investments represented approximately 51.9% and 56.5% of the total fair value of the Company’s equity investments as of June 30, 2024 and December 31, 2023, respectively. Investment Collateral In the majority of cases, the Company collateralizes its investments by obtaining a first priority security interest in a portfolio company’s assets, which may include its intellectual property. In other cases, the Company may obtain a negative pledge covering a company’s intellectual property. The Company's investments were collateralized as follows as of June 30, 2024 and December 31, 2023:
| Percentage of debt investments (at fair value), as of
| June 30, 2024 |  | December 31, 2023
Senior Secured First Lien |  |  |
All assets including intellectual property | 61.0 | % |  | 52.3 | %
All assets with negative pledge on intellectual property | 18.5 | % |  | 24.0 | %
“Last-out” with security interest in all of the assets | 10.6 | % |  | 12.5 | %
Total senior secured first lien position | 90.1 | % |  | 88.8 | %
Second lien | 7.8 | % |  | 8.9 | %
Unsecured | 2.1 | % |  | 2.3 | %
Total debt investments at fair value | 100.0 | % |  | 100.0 | %
Derivative Instruments The Company enters into forward currency contracts from time to time to help mitigate the impact that an adverse change in foreign exchange rates would have on the value of the Company’s investments denominated in foreign currencies. The following is a summary of the fair value and location of the Company’s derivative instruments in the Consolidated Statements of Assets and Liabilities held as of June 30, 2024 and December 31, 2023:
(in thousands) |  | Fair Value
Derivative Instrument | Statement Location |  | June 30, 2024 |  | December 31, 2023
Foreign currency forward contract | Other assets |  | $ | 188 |  |  | $ | — |
Foreign currency forward contract | Accounts payable and accrued liabilities |  | — |  |  | 766 |
| Total |  | $ | 188 |  |  | $ | 766 |
Net realized and unrealized gains and losses on derivative instruments recorded by the Company during the three and six months ended June 30, 2024 and 2023 are in the following locations in the Consolidated Statements of Operations:
(in thousands) |  |  | Three Months Ended June 30, |  | Six Months Ended June 30,
Derivative Instrument | Statement Location |  | 2024 |  | 2023 |  | 2024 |  | 2023
Foreign currency forward contract | Net realized gain (loss) - Non-control / Non-affiliate investments |  | $ | (849) |  |  | $ | — |  |  | $ | (849) |  |  | $ | — |
Foreign currency forward contract | Net change in unrealized appreciation (depreciation) - Non-control / Non-affiliate investments |  | 725 |  |  | (554) |  |  | 954 |  |  | (554) |
| Total |  | $ | (124) |  |  | $ | (554) |  |  | $ | 105 |  |  | $ | (554) |
Investment Income The Company’s investment portfolio generates interest, fee, and dividend income. The composition of the Company’s interest income and fee income is as follows:
(in thousands) | Three Months Ended June 30, |  | Six Months Ended June 30,
| 2024 |  | 2023 |  | 2024 |  | 2023
Contractual interest income | $ | 87,439 |  |  | $ | 86,147 |  |  | $ | 178,153 |  |  | $ | 168,938 |
Exit fee interest income | 10,592 |  |  | 14,054 |  |  | 22,472 |  |  | 23,436 |
PIK interest income | 15,267 |  |  | 5,819 |  |  | 25,164 |  |  | 11,347 |
Dividend income | 2,100 |  |  | — |  |  | 3,700 |  |  | — |
Other investment income(1) | 2,131 |  |  | 2,966 |  |  | 3,819 |  |  | 5,162 |
Total interest and dividend income | $ | 117,529 |  |  | $ | 108,986 |  |  | $ | 233,308 |  |  | $ | 208,883 |
(1)Other investment income includes OID interest income and interest recorded on other assets.
(in thousands) | Three Months Ended June 30, |  | Six Months Ended June 30,
| 2024 |  | 2023 |  | 2024 |  | 2023
Recurring fee income | $ | 2,203 |  |  | $ | 2,135 |  |  | $ | 4,658 |  |  | $ | 4,175 |
Fee income - expired commitments | 730 |  |  | 108 |  |  | 1,377 |  |  | 351 |
Accelerated fee income - early repayments | 4,544 |  |  | 5,002 |  |  | 7,216 |  |  | 7,912 |
Total fee income | $ | 7,477 |  |  | $ | 7,245 |  |  | $ | 13,251 |  |  | $ | 12,438 |
As of June 30, 2024 and December 31, 2023, unamortized capitalized fee income was recorded as follows:
(in millions) | June 30, 2024 |  | December 31, 2023
Offset against debt investment cost | $ | 38.1 |  |  | $ | 32.9 |
Deferred obligation contingent on funding or other milestone | 10.5 |  |  | 9.4 |
Total Unamortized Fee Income | $ | 48.6 |  |  | $ | 42.3 |
As of June 30, 2024 and December 31, 2023, loan exit fees receivable were recorded as follows:
(in millions) | June 30, 2024 |  | December 31, 2023
Included within debt investment cost | $ | 36.8 |  |  | $ | 35.9 |
Deferred receivable related to expired commitments | 5.2 |  |  | 4.3 |
Total Exit Fees Receivable | $ | 42.0 |  |  | $ | 40.2 |

X
- Definition The entire disclosure for investments owned by investment company. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/946-320/tableOfContent Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column A)(Footnote 1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column C)(Footnote 8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column F)(Footnote 5)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column A)(Footnote 8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3 + Details
Name: | us-gaap_InvestmentHoldingsScheduleOfInvestmentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_ScheduleOfInvestmentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration